By Fineline Cube 
China’s Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) announced that it has received clinical clearance from the National Medical Products Administration (NMPA) to investigate its albenatide (CJC‑1134‑PC) for weight loss applications.
Drug Profile
Albenatide is a Category 1 innovative drug candidate and a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA). It has been modified with Drug Affinity Complex (DAC) technology based on exenatide. Previously, the drug received approval for clinical trials in diabetes in China.
Development Strategy
Changshan Biochemical plans to leverage the drug’s potential in both weight management and diabetes treatment, with the clinical trial for weight loss marking a significant step in expanding its therapeutic applications.-Fineline Info & Tech